Apolipoproteins B
"Apolipoproteins B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA.
Descriptor ID |
D001055
|
MeSH Number(s) |
D10.532.091.300 D12.776.070.400.300 D12.776.521.120.300
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Apolipoproteins B".
Below are MeSH descriptors whose meaning is more specific than "Apolipoproteins B".
This graph shows the total number of publications written about "Apolipoproteins B" by people in this website by year, and whether "Apolipoproteins B" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 2 | 3 | 1996 | 1 | 0 | 1 | 1997 | 1 | 0 | 1 | 1998 | 0 | 1 | 1 | 1999 | 2 | 1 | 3 | 2001 | 0 | 1 | 1 | 2003 | 1 | 0 | 1 | 2004 | 1 | 0 | 1 | 2007 | 1 | 0 | 1 | 2008 | 1 | 0 | 1 | 2009 | 1 | 1 | 2 | 2011 | 0 | 1 | 1 | 2012 | 2 | 1 | 3 | 2013 | 1 | 0 | 1 | 2014 | 1 | 1 | 2 | 2015 | 1 | 0 | 1 | 2016 | 0 | 1 | 1 | 2017 | 0 | 1 | 1 | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Apolipoproteins B" by people in Profiles.
-
Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
-
Hagstr?m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 08 30; 146(9):657-672.
-
Malaney JL, Demboski JR, Cook JA. Integrative species delimitation of the widespread North American jumping mice (Zapodinae). Mol Phylogenet Evol. 2017 09; 114:137-152.
-
Harris RA, Alcott CE, Sullivan EL, Takahashi D, McCurdy CE, Comstock S, Baquero K, Blundell P, Frias AE, Kahr M, Suter M, Wesolowski S, Friedman JE, Grove KL, Aagaard KM. Genomic Variants Associated with Resistance to High Fat Diet Induced Obesity in a Primate Model. Sci Rep. 2016 11 04; 6:36123.
-
Manifold-Wheeler BC, Elmore BO, Triplett KD, Castleman MJ, Otto M, Hall PR. Serum Lipoproteins Are Critical for Pulmonary Innate Defense against Staphylococcus aureus Quorum Sensing. J Immunol. 2016 Jan 01; 196(1):328-35.
-
Bjornstad P, Eckel RH, Pyle L, Rewers M, Maahs DM, Snell-Bergeon JK. Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus. Am J Cardiol. 2015 Oct 01; 116(7):1057-62.
-
Bjornstad P, Nguyen N, Reinick C, Maahs DM, Bishop FK, Clements SA, Snell-Bergeon JK, Lieberman R, Pyle L, Daniels SR, Paul Wadwa R. Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes. Acta Diabetol. 2015 Jun; 52(3):611-9.
-
Niemsiri V, Wang X, Pirim D, Radwan ZH, Hokanson JE, Hamman RF, Barmada MM, Demirci FY, Kamboh MI. Impact of genetic variants in human scavenger receptor class B type I (SCARB1) on plasma lipid traits. Circ Cardiovasc Genet. 2014 Dec; 7(6):838-47.
-
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
-
Hall PR, Elmore BO, Spang CH, Alexander SM, Manifold-Wheeler BC, Castleman MJ, Daly SM, Peterson MM, Sully EK, Femling JK, Otto M, Horswill AR, Timmins GS, Gresham HD. Nox2 modification of LDL is essential for optimal apolipoprotein B-mediated control of agr type III Staphylococcus aureus quorum-sensing. PLoS Pathog. 2013 Feb; 9(2):e1003166.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|